ResearcherÜmraniye Eğitim ve Araştırma HastanesiActive in the last 2 years

Melike Özçelik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0406-715X; OpenAlex author ID A5067518254. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2025: 1 paper · 2026: 2 papers

Papers 3

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-026-47335-7 ↗
Prognostic Impact of Ectopic Fat Deposition Within the Psoas Muscle in Patients with Stage IV Pancreatic Cancer Receiving Systemic Chemotherapy. Last author DOI 10.3390/jcm15103936 ↗
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-025-96157-6 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nargız Majidova · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
İlkay Gültürk · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Abdullah Sakin · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Yasin Sezgin · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Bilgin Demir · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Yakup Ergün · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
İbrahim Çil · 1 shared paper, 2026 · strength 0.27
- Paper Prognostic Impact of Ectopic Fat Deposition Within the Psoas Muscle in Patients with Stage IV Pancreatic Cancer Receivi… DOI 10.3390/jcm15103936 ↗
Mustafa Yıldırım · 1 shared paper, 2025 · strength 0.16
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.